Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
6.43
+0.35 (5.76%)
At close: Oct 6, 2025, 4:00 PM EDT
6.52
+0.09 (1.38%)
After-hours: Oct 6, 2025, 7:18 PM EDT
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
162.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 686.88K | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CYBN News
- 13 days ago - Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire
- 25 days ago - CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 25 days ago - Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - Business Wire
- 4 weeks ago - Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire
- 4 weeks ago - Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 4 weeks ago - Cybin to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
- 4 weeks ago - Cybin Announces Senior Leadership Changes - Business Wire
- 5 weeks ago - Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire